Sensei Biotherapeutics (NASDAQ:FTH) Sets New 1-Year High – Here’s Why

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $41.16 and last traded at $40.9250, with a volume of 274991 shares. The stock had previously closed at $40.05.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on FTH shares. Oppenheimer began coverage on shares of Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price objective for the company. Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. Wall Street Zen raised shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Raymond James Financial started coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They set an “outperform” rating and a $56.00 price target for the company. Finally, Loop Capital set a $50.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Sensei Biotherapeutics Stock Up 1.3%

The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -0.29 and a beta of -0.28. The firm’s 50 day simple moving average is $30.19.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. As a group, sell-side analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Anand Kiran Parikh acquired 2,806 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was acquired at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This represents a 0.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brian C. Stephenson acquired 9,391 shares of the stock in a transaction dated Wednesday, June 24th. The shares were bought at an average cost of $26.13 per share, with a total value of $245,386.83. Following the completion of the transaction, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This represents a 53.93% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of large investors have recently modified their holdings of FTH. Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics during the 1st quarter worth $22,758,000. Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics in the second quarter valued at $3,610,000. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Bank of America Corp DE boosted its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares in the last quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.